Thiazolidinediones, SGLT2 inhibitors, metformin, and DPP4 antagonists have also been reported to have favorable effects on NAFLD in T2DM patients [33,34]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.